<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">Antiphospholipid syndrome</z:e> is characterized by venous and <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo>, <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo>, <z:hpo ids='HP_0001297'>stroke</z:hpo> and, rarely, <z:hpo ids='HP_0011009'>acute</z:hpo> coronary syndromes </plain></SENT>
<SENT sid="1" pm="."><plain>However, there are no data available regarding the management of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> in <z:e sem="disease" ids="C0409980" disease_type="Disease or Syndrome" abbrv="">primary antiphospholipid syndrome</z:e> with accompanying severe <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> and cardiogenic shock </plain></SENT>
<SENT sid="2" pm="."><plain>We describe such a case, which was managed by successful primary percutaneous transluminal coronary angioplasty and stent implantation with accompanying immunosuppression therapy </plain></SENT>
</text></document>